Clinical Trials & Research
Search Clinical Trials
|Title||Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia|
|Description||The trial is studying lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.|
Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cell. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood.
It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years and older
* Patient must have Myelodysplastic syndromes (MDS) lasting = 3 months according to WHO criteria.
* Patient must not be pregnant
|Principal Investigator||Amit Verma, MD|
|Contact Name||Dale Wyville, PA|
|Current Trial Type||Interventional|
|Montefiore Clinical Trial||No|
|CHAM Clinical Trial||No|